Revance Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Revance Therapeutics, Inc.
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
With a virtual visit to SciVac in Israel, a belated Revance site inspection in California and two weeks at a Dr. Reddy’s site in India, the US FDA finds ways to overcome travel restrictions in its efforts to oversee drug manufacturing quality.
- Site Specific
- Topical Delivery
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Essentia Biosystems, Inc.